AGENDA ITEM | PRESIDER/PRESENTER(s)
--- | ---
**Wednesday, February 27**
8:00 | **Welcome & Introductions**
Dr. Jose Romero (ACIP Chair)
Dr. Amanda Cohn (ACIP Executive Secretary; CDC)

8:20 | **Japanese Encephalitis Vaccine**
Introduction
Dr. Chip Walter (ACIP, WG Chair)
Background and review
Dr. Susan Hills (CDC/NCEZID)
Updated recommendations for U.S. travelers
Dr. Susan Hills (CDC/NCEZID)
Accelerated primary series in adults
Dr. Susan Hills (CDC/NCEZID)
Booster dose recommendations
Dr. Susan Hills (CDC/NCEZID)

9:20 | **Break**

9:30 | **Anthrax Vaccines**
Introduction
Dr. David Stephens (ACIP, WG Chair)
AV7909 (NuThrax)
Dr. William Bower (CDC/NCEZID)
Preexposure AVA booster dose interval
Dr. William Bower (CDC/NCEZID)

10:30 | **Break**

10:40 | **Influenza Vaccines**
Introduction
Dr. Chip Walter
Surveillance update
Ms. Lynnette Brammer (CDC/NCIRD)
VE update
Dr. Brendan Flannery (CDC/NCIRD)
Afluria quadrivalent for children aged 6 through 59 months
Dr. Gregg Sylvester (Seqirus)
Inactivated influenza vaccine and spontaneous abortion in the
Vaccine Safety Datalink
Dr. James Donahue (Marshfield Clinic)
Summary and work group considerations
Dr. Lisa Grohskopf (CDC/NCIRD)

12:00 | **Lunch**

1:00 | **Human Papillomavirus Vaccines**
Introduction
Dr. Peter Szilagyi (ACIP, WG Chair)
Overview and background
Dr. Lauri Markowitz (CDC/NCIRD)
Impact and cost effectiveness of mid-adult HPV vaccination
Dr. Marc Brisson (Laval University)
Overview of health economic results from 4 modeling groups
Dr. Harrell Chesson (CDC/NCHSTP)
Mid-adult HPV vaccination: patient values and acceptability
Dr. Nancy McClung (CDC/NCIRD)
Program and vaccine provider surveys
Dr. Elissa Meites (CDC/NCIRD)
Work group considerations
Dr. Lauri Markowitz (CDC/NCIRD)

2:30 | **Break**

2:40 | **Combination Vaccines**
Introduction
Dr. Kelly Moore (ACIP, WG Chair)
Immunogenicity and safety of a pediatric hexavalent vaccine
Dr. Andrew Lee (Merck)
Hib vaccines in AI/AN population
Dr. Laura Hammitt (Johns Hopkins University)
Summary, review of work group considerations
Dr. Sara Oliver (CDC/NCIRD)

3:30 | **Break**

3:40 | **Public Comment**

4:55 | **Break**

5:00 | **VOTES**
Japanese Encephalitis Vaccine
Dr. Susan Hills (CDC/NCEZID)
Anthrax Vaccines
Dr. William Bower (CDC/NCEZID)

5:30 | **Adjourn**

---

This document has been archived for historical purposes. (2/25/2019)
8:00  **Agency Updates & Unfinished Business**

**CDC, CMS, DoD, DVA, FDA, HRSA, IHS, NIH, NVPO**

Dr. Nancy Messonnier (CDC/NCIRD); *Ex Officio* Members

---

8:30  **Pneumococcal Vaccines**

**Introduction**

PCV13 direct and indirect effects on serotype 3 disease

Dr. Grace Lee (ACIP, WG Chair)

PCV13 direct effects on pneumonia hospitalizations in adults

Dr. Tamara Pilishvili (CDC/NCIRD)

Comparison of economic analyses of PCV13 use among adults ≥65 years old

Dr. Fernanda Lessa (CDC/NCIRD)

GRADE and Evidence to Recommendations (EtR) for PCV13 use among adults ≥65 years old in the context of indirect effects experience to date

Dr. Andrew Leidner (CDC/NCIRD)

---

10:30  **Meningococcal Vaccines**

**Introduction**

Immunogenicity and safety of a MenB-FHbp booster dose

Dr. David Stephens (ACIP, WG Chair)

Immunogenicity and safety of a MenB-4C booster dose

Dr. Paul Balmer (Pfizer)

GRADE and Evidence to Recommendations Framework for MenB booster doses

Dr. Phil Watson (GSK)

Work Group interpretation of data, considerations, and next steps

Dr. Catherine Bozio (CDC/NCIRD)

---

11:55  **Zoster Vaccines**

**Introduction**

Zoster vaccine uptake and supply

Dr. Kelly Moore (ACIP, WG Chair)

RZV safety update

Dr. Kathleen Dooling (CDC/NCIRD)

Dr. Tom Shimabukuro (CDC/NCEZID)

---

1:00  **Hepatitis Vaccines**

**Introduction**

Background: HepA vaccines and persons with HIV infection

Dr. Kelly Moore (ACIP, WG Chair)

GRADE: Use of HepA vaccines among persons with HIV infection

Ms. Alaya Koneru (CDC/NCHHSTP)

Evidence to Recommendation Framework: Use of HepA vaccines among persons with HIV infection

Dr. Mark Weng (CDC/NCHHSTP)

---

2:35  **Vaccine Supply**

2:40  **Adjourn**

---

**Acronyms**

AI/AN  American Indian/Alaska Native

AVA  Anthrax vaccine absorbed

CDC  Centers for Disease Control & Prevention

CMS  Centers for Medicare and Medicaid Services

DoD  Department of Defense

DVA  Department of Veterans Affairs

EtR  Evidence to Recommendations Framework

FDA  Food and Drug Administration

GRADE  Grading of Recommendations Assessment, Development and Evaluation

Hib  *Haemophilus influenzae* type b

HRSA  Health Resources and Services Administration

IHS  Indian Health Service

MenB  Serogroup B meningococcal vaccine

NCHHSTP  National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]

NCIRD  National Center for Immunization & Respiratory Diseases [of CDC/OID]

NCEZID  National Center for Emerging and Zoonotic Diseases [of CDC/OID]

NVPO  National Vaccine Program Office

PCV13  13-valent pneumococcal conjugate vaccine

RZV  Recombinant zoster vaccine

WG  Work Group